Cisatracurium Hameln Injection
Cisatracurium
2mg/ml
ZAS Corporation
| Pack size | |
|---|---|
| Unite Price | 520.00 BDT |
Indications
Cisatracurium Hameln Injection is used for:
Facilitate mechanical ventilation in intensive care, Facilitate endotracheal intubation, Muscle relaxant in general anaesthesia
Adult Dose
Intravenous
Facilitate mechanical ventilation in intensive care, Facilitate endotracheal intubation, Muscle relaxant in general anaesthesia
Adult: Initially, 150 mcg/kg by inj.
Maintenance: 30 mcg/kg by inj (each dose provides 20 min of additional block), may also be given by infusion at an initial rate of 3 mcg/kg/min followed by a rate of 1-2 mcg/kg/min.
Child Dose
Intravenous
Facilitate mechanical ventilation in intensive care, Facilitate endotracheal intubation, Muscle relaxant in general anaesthesia
Child: 1-23 mth Initially, 150 mcg/kg by inj over 5-10 sec, during halothane or opiate anaesth; 2-12 yr Initially, 100-150 mcg/kg by inj over 5-10 sec, during halothane or opiate anaesth.
Maintenance: 20 mcg/kg by inj (each dose provides 9 min of additional block), may also be given by infusion at an initial rate of 3 mcg/kg/min followed by a rate of 1-2 mcg/kg/min.
Renal Dose
Administration
IV Preparation
Dilute in D5W, NS or D5/NS
As low as 0.1 mg/mL can be stored at room temp or refrigerated for 24 hr
Contra Indications
Hypersensitivity to cisatracurium (or benzyl alcohol if 10 mL vial is used)
Use of 10 mL vial in pediatric patients <1 month of age and low birth-weight infants (contains benzyl alcohol)
Precautions
Patient w/ burn injury, neuromuscular disease (e.g. myasthenia gravis, Eaton-Lambert syndrome), electrolyte abnormalities, hemiparesis or paraparesis, carcinomatosis. Childn. Pregnancy and lactation. Monitoring Parameters Monitor heart rate, BP, resp rate; peripheral nerve stimulator twitch response (when appropriate).
Pregnancy-Lactation
Pregnancy
There are no adequate and well-controlled studies in pregnant women; animal studies conducted in rats administered cisatracurium besylate during organogenesis found no evidence of fetal harm at 0.8 times (ventilated rats) the exposure from a human starting IV bolus dose of 0.2 mg/kg
Labor or delivery
The action of neuromuscular blocking agents may be enhanced by magnesium salts administered for management of preeclampsia or eclampsia of pregnancy
Lactation
It is not known whether drug is present in human milk; developmental and health benefits of breastfeeding should be considered along with mother's clinical need for therapy and any potential adverse effects on breastfed child from treatment or from underlying maternal condition
Interactions
Increased effect w/ anaesth agents (e.g. enflurane, isoflurane, halothane, ketamine), other non-depolarising neuromuscular blocking agents, certain antibiotics (e.g. aminoglycosides, polymyxins, spectinomycin, tetracyclines, lincomycin, clindamycin), anti-arrhythmic drugs (e.g. propranolol, Ca channel blockers, lidocaine, procainamide, quinidine), diuretics (e.g. furosemide, and possibly thiazides, mannitol and acetazolamide), Mg and lithium salts, ganglion blocking drugs (e.g. trimetaphan, hexamethonium). Decreased effect w/ phenytoin, carbamazepine, anticholinesterases (e.g. donepezil).
Side Effects
Side effects of Cisatracurium :
<1%
Bronchospasm
Bradycardia
Flushing
Pruritus
Myositis ossificans
Hypotension
Rash
Mode of Action
Cisatracurium antagonises the action of acetylcholine by binding to cholinergic receptors on the motor end-plate, resulting in a competitive block of neuromuscular transmission.
Note
Cisatracurium Hameln 2mg/ml Injection generic name is Cisatracurium. Cisatracurium Hameln 2mg/ml Injection is manufactured by ZAS CorporationCisatracurium Hameln is availble in all over Bangladesh.
Mes BD drug index information on Cisatracurium Hameln Injection is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.